Cancer is a disease caused by mutations in genes or DNA in the genome of human cells . This mutation may occur spontaneously from the error during DNA synthesis or be triggered by exposure to toxins or carcinogens in food, water, air, and environment. The mutated cells are thus divided at an abnormal rate and turn into cancer cells.
At present, cancer is the number one cause of death for Thai people. The number of cancer patients is increasing every year. There are approximately 170,000 new cancer patients with 114,000 deaths each year which account for 313 deaths per day or 12 per hour.
The most common type of cancer in The Thai population is lung cancer. But if classified based on gender, the most common type of cancer in women is breast cancer while the most common type of cancer in men is liver and bile duct cancers. This data emphasizes the negative socio-economic impact caused by cancer in Thailand.
As different types of cancer confer distinct characteristics, the treatments are varied. Standard cancer treatment methods are surgery, radiotherapy, chemotherapy, and targeted therapy using drug treatment or biological matter, such as monoclonal antibodies.
However, a new effective and specific treatment is being developed namely cellular immunotherapy. This method is currently under investigation both in laboratory and clinical settings.
Cellular immunotherapy is the method that utilizes a patient's immune cells, which are low in number and function, to stimulate or modify in the laboratory to improve their anti-cancer function. The activated immune cells are expanded and re-infused back into the patient's body to act as a living drug for cancer treatment. This method is safe as the patient's own immune cells are used to treat the patient. The safety and efficacy of this strategy were also demonstrated in clinical trials.
At SiCORE-CIT, 3 types of cellular immunotherapy technology platforms that we are currently developing are...
> BiTEs
First, we develop the immune cells manipulation technique which calls Self-differentiated Myeloid-derived Antigen-presenting-cells Reactive against Tumors-Dendritic cells or SMART DCs from monocytes. These SMART DCs can specifically present cancer antigens and activate T cells. The SMART DCs activated T cells exhibited improved anticancer activity than conventional DCs.
> Chimeric antigen receptor T cells
The second platform is Chimeric antigen receptor T cells or CAR T cells. We engineer one of the immune cells called T cells to express CAR molecules which allow cancer antigen recognition and lead to cancer cell lysis in an MHC-independent manner. Through this strategy, T cell activation by DC was unnecessary.
Thirdly, we also engineer T cells to secrete the Bi-specific engager molecule (Bi-specific T-cell engagers or BiTEs). The BiTEs are designed to contain 2 domains. One domain binds with cancer antigen on the cancer cells while the other binds to the protein on T cells, thus bridging cancer cells and T cells and results in cancer cell lysis.
At the Siriraj Center of Research Excellence for Cancer Immunotherapy, researches are being performed on several types of cancer separated into 5 research groups such as
(See more about the research groups, HERE)